바카라 온라인 files patent infringement lawsuit against Vertex Pharmaceuticals in UK: “Our technology used in developing CASGEVY”

[by Ji, Yong Jun] 바카라 온라인, a gene editing company, announced on April 21 that it has filed a patent infringement lawsuit in the British court against Vertex Pharmaceuticals and its commercial partners, Lonza and RoslinCT, concerning the gene editing treatment CASGEVY.

바카라 온라인 secured a patent for its 'CRISPR RNP (Ribonucleoprotein, protein-nucleic acid complex)' technology, a method for delivering Cas9 into cells in protein form, in Europe and Japan in October 2024. According to the company, CRISPR mitigates cytotoxicity commonly associated with DNA and mRNA delivery methods. It also offers excellent safety by eliminating the risk of foreign DNA integration into the genome and demonstrating low off-target effects. CRISPR RNP is widely employed in the development of therapeutics as well as in the genetic editing of plants and animals.

CASGEVY is the world's first gene editing treatment to obtain marketing approval from the European Commission (EC) in February of last year, following its initial approval in the UK in November 2023. The therapy offers a novel treatment option for patients with sickle cell disease and β-thalassemia (Mediterranean anemia). A single dose is priced at approximately USD 2.2 million (around KRW 3.1 billion), and the product is anticipated to achieve blockbuster-level sales. In a related development, Vertex entered into a licensing agreement with Editas Medicine in December 2023, valued at USD 100 million, securing access to CRISPR Cas9 바카라 온라인.

"Vertex's CASGEVY was developed using 바카라 온라인's CRISPR RNP technology," said Ryu Jong-sang, CEO of 바카라 온라인. "We expect Vertex to recognize the use of 바카라 온라인's CRISPR-Cas9 and CRISPR RNP technologies and to provide fair compensation accordingly."

"This patent infringement lawsuit is not about restricting access to CASGEVY for patients in the UK but about ensuring that 바카라 온라인 receives fair compensation for its technology through a reasonable licensing agreement," Ryu further emphasized.